FILSPARI (sparsentan): Use in Patients With Severely Decreased eGFR in IgA Nephropathy
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
FILSPARI (sparsentan): Changes in Blood Pressure and Hypotensive Events in FSGS
FILSPARI (sparsentan): Effect on Estimated Glomerular Filtration Rate (eGFR) in FSGS
FILSPARI (sparsentan): Dosing and Administration in Clinical Trials of FSGS
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
FILSPARI (sparsentan) – 2-Year Results from the Phase 3 PROTECT Study Published in The Lancet
Physiologically-Based Pharmacokinetic Model of Sparsentan to Evaluate Drug-Drug Interaction Potential
Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results From a Randomised Active-Controlled Phase 3 Trial
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy
FILSPARI (sparsentan) – 2-Year Results from the Phase 3 DUPLEX Study Published in the NEJM
Sparsentan receptor occupancy modeling, clinical actions, and safety
Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial